AcelRx Pharmaceuticals
AcelRx Pharmaceuticals | Therapies for Acute Pain.
Launch date
Employees
Market cap
AUD23.6m
Enterprise valuation
AUD24m (Public information from Sep 2024)
Share price
$0.9414 ACRX
Redwood City California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 5.4m | 2.8m | 1.8m | <1m | <1m | <1m | 7.1m |
| % growth | 137 % | (48 %) | (37 %) | (63 %) | 5 % | (72 %) | 3582 % |
| EBITDA | (37.1m) | (30.8m) | (30.2m) | - | - | - | - |
| % EBITDA margin | (684 %) | (1094 %) | (1704 %) | - | - | - | - |
| Profit | (40.4m) | (35.1m) | 47.8m | (18.4m) | (18.9m) | (25.9m) | (23.5m) |
| % profit margin | (746 %) | (1246 %) | 2696 % | (2826 %) | (2769 %) | (13399 %) | (330 %) |
| EV / revenue | 18.7x | 27.2x | 10.5x | 19.1x | 25.9x | 91.4x | 2.5x |
| EV / EBITDA | -2.7x | -2.5x | -0.6x | - | - | - | - |
| R&D budget | 4.0m | 4.1m | 5.2m | - | - | - | - |
| R&D % of revenue | 74 % | 145 % | 293 % | - | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $14.8m | Early VC | |
| N/A | $8.0m | Debt | |
| N/A | N/A | IPO | |
| N/A | $20.8m | Post IPO Debt | |
| N/A | $10.0m | Post IPO Equity | |
$40.0m | Debt | ||
$25.0m | Post IPO Debt | ||
| N/A | $27.5m | Post IPO Equity | |
| N/A | $14.0m | Post IPO Equity | |
* | N/A | $7.5m | Post IPO Equity |
* | N/A | $10.0m | Post IPO Equity |
* | N/A | $8.0m | Debt |
| Total Funding | AUD22.9m | ||
Related Content
Recent News about AcelRx Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by AcelRx Pharmaceuticals
Edit
ACQUISITION by La jolla Pharmaceutical Jul 2020